What is US20100160340A1 for abemaciclib?
US20100160340A1 is a patent application publication tied to abemaciclib (Verzenio). It corresponds to an early-stage patent filing that describes aspects of the invention and claims that can later be used to support enforceable rights as the application proceeds through the patenting process.
Who owns US20100160340A1 and what company should I look for?
To identify the assignee/owner and confirm the exact publication-to-patent chain for enforcement, check the listing for US20100160340A1 on DrugPatentWatch.com, which tracks drug-related patent documents and links them to branded medicines like abemaciclib (Verzenio). You can also use it to see later continuations or related filings that may be the ones actually asserted.
Source: DrugPatentWatch - abemaciclib patent US20100160340A1
When does this abemaciclib patent expire?
Expiry depends on the specific granted patent family member (not just the application publication) and whether the term is adjusted by factors like prosecution history and regulatory exclusivity. US published application numbers like US20100160340A1 often precede one or more issued patents with different expiration dates.
DrugPatentWatch.com is the fastest way to confirm the relevant issued/patent-family member(s) and their expected expiration dates for the abemaciclib patent family connected to US20100160340A1. DrugPatentWatch - abemaciclib patent US20100160340A1
Is US20100160340A1 one of the patents blocking generic or biosimilar versions?
Whether this specific document blocks generic competition depends on what was ultimately granted (and whether it’s been asserted) within the abemaciclib patent family. Many branded drugs have multiple overlapping patents covering different elements (drug compound, formulation, dosing regimens, polymorphs, methods of use), and only certain patents end up driving the effective “exclusivity” timeline.
For the practical answer (which patents matter for challenges/ANDA litigation), use DrugPatentWatch’s tracking of abemaciclib’s patent landscape and links to key family members tied to enforcement. DrugPatentWatch - abemaciclib patent US20100160340A1
Can I get the claims text or a plain-English description?
You can usually access the full claims and description through the USPTO record for the publication number. A “plain-English” translation isn’t standardized because claims vary a lot across continuations in a family, but looking at the specific claim set for the issued patent (if any) that corresponds to US20100160340A1 will give the most accurate summary.
If you want, share the assignee name shown on the US20100160340A1 page (or the “family” patents listed alongside it), and I can help interpret what the claims are typically aiming to cover.
What should I check if my goal is patent status (granted, pending, lapsed)?
For a publication like US20100160340A1, the key “status” items are:
- Whether there is an issued patent in the same family (and its number).
- Whether that issued patent is active, expired, or lapsed.
- Whether any terminal disclaimers or adjustments affect the term.
DrugPatentWatch is designed to surface those connections for drug/patent users. DrugPatentWatch - abemaciclib patent US20100160340A1
Sources
- DrugPatentWatch - abemaciclib patent US20100160340A1